Previous 10 | Next 10 |
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acquire the business of GenePOC Inc., a Quebec City, Quebec, Cana...
Meridian Bioscience (NASDAQ: VIVO ): Q2 Non-GAAP EPS of $0.19 beats by $0.04 ; GAAP EPS of $0.17. More news on: Meridian Bioscience, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Meridian Bioscience (NASDAQ: VIVO ) has agreed to acquire Quebec City-based GenePOC , a developer of molecular diagnostic instruments and assays, for $50M in upfront cash plus up to $70M based on the achievement of certain development and sales milestones. More news on: Meridian Bioscie...
U.S. Legislation Update The inevitability of cannabis legalization across the United States is becoming more and more clear. In addition to numerous states advancing pro-cannabis bills through their legislatures and broad public support for legalization, the U.S. Congress is expected to ...
AMRC , AOS , APRN , ARCC , ARNC , AROC , BHGE , BP , CCEP , CDK , CEQP , CHTR , CMI , CNX , CNXM , COP , CRI , CRTO , CVLT , DBD , EAT , ECA , ECL , EEFT , EIGI , EME , EQM , ETM , ETN , EXLS , FDC , FDP , FIS , FLWS , GDI , GE , GEO , GLDD , GLT , GL...
CINCINNATI, April 18, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve DNA target amplification and quantification from crude samples; adding to its growing portfo...
CINCINNATI, April 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019 financial results Tuesday, April 30, 2019. Jack Kenny, Chief Executive Officer, and Eric Rasm...
Blueprint Medicines (NASDAQ: BPMC ) initiated with Overweight rating and $112 (34% upside) price target at Morgan Stanley. More news on: Blueprint Medicines Corporation, iRhythm Technologies, Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Gainers: AVEO Pharmaceuticals (NASDAQ: AVEO ) +35% . ADMA Biologics (NASDAQ: ADMA ) +32% . Sangamo Therapeutics (NASDAQ: SGMO ) +27% . Castor Maritime (NASDAQ: CTRM ) +24% . EDAP TMS S.A. (NASDAQ: EDAP ) +23% . Riot Blockchain (NASDAQ: RIOT ) +22% . Vaccinex (NASDAQ: VCNX ) +1...
Meridian Bioscience (NASDAQ: VIVO ) provides preliminary Q2 sales and revised FY 2019 guidance. More news on: Meridian Bioscience, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...